Oruka Therapeutics, Inc.
ORKA
Rank in Stocks
#3302
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Share Price
$80.01
Last synced: 2026-10-21
Market Cap
$5.30B
Change (1 day)
1.16%
Change (1 year)
200.21%
Country
US
Trade Oruka Therapeutics, Inc. (ORKA)
Category
Healthcare
Dividend yield history for Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (stock symbol: ORKA) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Oruka Therapeutics, Inc. (ORKA) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
